GlassScriptPhysician profile
Sara A Jones
NPI 1003057167
$7,838.34
in general payments reported to CMS, 2019-2025
67 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $797 · 2022: $1,418 · 2023: $1,898 · 2024: $1,969 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,533 · Consulting Fee: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,532.98 |
| Consulting Fee | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,067.00 | 2021-2025 | |
| Janssen Biotech, INC. | $667.38 | 2021-2025 | Rybrevant, Talvey, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $366.26 | 2021-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $294.97 | 2021-2025 | Tagrisso, Calquence, Enhertu |
| Genzyme Corporation | $294.70 | 2021-2025 | |
| Celgene Corporation | $294.19 | 2021-2025 | Reblozyl, Onureg |
| Amgen INC. | $288.17 | 2021-2023 | Xgeva, Vectibix, Nplate |
| Pfizer INC. | $284.93 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $277.74 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $250.35 | 2021-2025 | Cresemba, Padcev, Vyloy |
| Genentech USA, INC. | $248.75 | 2021-2025 | Lunsumio, Venclexta, Polivy |
| Takeda Pharmaceuticals U.S.A., INC. | $211.31 | 2021-2024 | Ninlaro, Alunbrig, Iclusig |
| Incyte Corporation | $204.21 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Abbvie INC. | $197.54 | 2021-2025 | |
| Daiichi Sankyo INC. | $188.94 | 2022-2025 | Enhertu, Injectafer |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.